Bristol-Myers Squibb's Hydrea reduces painful sickle cell anemia episodes by 50% -- NHLBI study.
BRISTOL-MYERS SQUIBB HYDREA REDUCES PAINFUL SICKLE CELL EPISODES BY 50% leading the National Heart, Lung & Blood Institute to halt the Multicenter Study of Hydroxyurea (MSH) in sickle cell anemia, NHLBI announced Jan. 30. The institute issued a same-day clinical alert to 5,000 U.S. physicians apprising them of the study results. In addition, the National Library of Medicine will place the alert on the MEDLINE system and the document will be faxed to medical school libraries.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth